Effects of monoclonal antibody daratumumab combined with ixazomib-based treatment regimen on survival of patients with relapsed/refractory multiple myeloma

Effects of monoclonal antibody daratumumab combined with ixazomib-based treatment regimen on survival of patients with relapsed/refractory multiple myeloma

Background/Aim. Combination therapy with daratumumab and ixazomib has been previously used for the treatment of multiple myeloma (MM), but treatment outcomes of these drugs and safety have not yet been confirmed. The aim of the study was to assess the effects of monoclonal antibody daratumumab in co...

Full description

Saved in:
Bibliographic Details
Main Authors: Peng Lang, He Jiawen, Zheng Ying, Zeng Qingfang
Format: Article
Language:English
Published: Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade 2025-01-01
Series:Vojnosanitetski Pregled
Subjects:
antineoplastic combined chemotherapy protocols
drug-related adverse effect and adverse reactions
immunotherapy
multiple myeloma
quality of life
survival
treatment outcome
Online Access:https://doiserbia.nb.rs/img/doi/0042-8450/2025/0042-84502500016P.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doiserbia.nb.rs/img/doi/0042-8450/2025/0042-84502500016P.pdf

Similar Items